Immuno-oncology at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

34 organizations at ENA 2026 present work in immunotherapy, immune engagers and the tumour microenvironment, led by universities and institutes. Between them they bring 80 presentations to the program. Most represented: Vall d'Hebron Institute of Oncology (VHIO), National Cancer Institute (NCI) and Biocytogen. As of Oct 13, 2026.

All 254 organizations at ENA 2026 →

Showing 1–8 of 34 organizations

Organization	ENA 2026 Attendance
Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain
vhio.net Cancer centres & hospitals Barcelona cancer research institute at Vall d'Hebron University Hospital, combining translational research with an early-phase clinical trials unit.	Session Wed Nov 18 1:30–1:35pm Opening Ceremony: Welcome and opening of the ENA 2026 Symposium Session Wed Nov 18 1:35–2:20pm Keynote Lecture: The rise of biotech in APAC Session Wed Nov 18 2:20–3:50pm Plenary Session 1: The next wave of immune engagers in cancer therapy: beyond CD3 and beyond T cells Immuno-oncology Talk Thu Nov 19 3:20–3:40pm Part of Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Targeting YAP/TEAD as monotherapy and in rational combinations Genomics Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Phase Ib study of OMO-103 in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma Targeted agents Session Fri Nov 20 8–9:30am Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Cell therapy Talk Fri Nov 20 8:40–9am Part of Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Neoantigen TCR-T Cell therapy Talk Fri Nov 20 9:45–10am Part of Workshop 7: Novel Methodologies & Endpoints in New Drug Development Multi-omics including Spatial Transcriptomics Early clinical Talk Fri Nov 20 12–12:10pm Part of Plenary Session 6: Proffered papers MYC Inhibition with OMO-103 Restores TNF-Superfamily Signaling and Uncovers Actionable Immunotherapy Vulnerabilities in KRAS-Mutant NSCLC Targeted agents · Immuno-oncology Session Fri Nov 20 3–4:50pm Plenary Session 7: Proffered papers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Novel clinical trial design Digital Remote Patient Monitoring in Early-Phase Oncology Clinical Trials: A Prospective Pilot Study of Feasibility and Implementation Early clinical Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models A preclinical patient-derived xenograft platform to model resistance to cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in oestrogen receptor-positive breast cancer. Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Integrative molecular profiling of a breast cancer (BC) patient-derived xenograft (PDX) platform for biomarker discovery Preclinical models
National Cancer Institute (NCI) Bethesda, Maryland
cancer.gov Agencies, groups & societies Federal agency within NIH that funds and conducts cancer research, including intramural labs and clinical trials.	Session Wed Nov 18 1:30–1:35pm Opening Ceremony: Welcome and opening of the ENA 2026 Symposium Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Comparison of CRISPR screens in two- and three-dimensional ovarian cancer models to identify architecture-dependent mechanisms of resistance to CHEK1 inhibition Targeted agents Session Thu Nov 19 10–11:30am Plenary Session 3: Proffered Papers Session Thu Nov 19 5–6:30pm Workshop 6: Tumour microenvironment Immuno-oncology Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology A novel virus-like drug conjugate for the treatment of cutaneous melanoma Immuno-oncology Session Fri Nov 20 8–9:30am Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Cell therapy Session Fri Nov 20 11:15am–12pm Keynote lecture: Immunotherapy innovations Immuno-oncology Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies ClpP Agonist-Induced Cellular Senescence Promotes Vulnerability to Apoptosis and Ferroptosis in Triple Negative Breast Cancers Targeted agents
Biocytogen Beijing, China
biocytogen.com CROs & CDMOsExhibitor Provides humanized mouse models, preclinical pharmacology and antibody discovery, and develops its own antibody and ADC candidates.	Booth Exhibiting at Booth 23 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates BCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors ADCs & radioligands Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology BCG024: A Novel DLL3×CD3×4-1BB Trispecific T Cell Engager Enhances T Cell Persistence and Functionality in Preclinical Models Immuno-oncology Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Animal Models The B-hCRBN Mice Model Facilitates PROTACs Studies Based on CRBN Ligands Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Animal Models Utilizing a Humanized CD8 Mouse Model for Non-clinical Studies of Cancer Immunotherapy Preclinical models
The Institute of Cancer Research London, UK
icr.ac.uk Universities & institutes London cancer research institute and college of the University of London, with a drug discovery centre; partnered with The Royal Marsden.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Dissecting tumour microenvironment signatures associated with chemoresistance in triple negative breast cancer Targeted agents Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Functional Genomics Targeted protein degradation models for the exploration of spliceosome-associated RNA helicases as therapeutic targets Genomics Session Thu Nov 19 5–6:30pm Workshop 6: Tumour microenvironment Immuno-oncology Talk Thu Nov 19 6–6:20pm Part of Workshop 6: Tumour microenvironment Exploiting fibroblast activation protein (FAP) in cancer therapy Immuno-oncology
Institute of Oncology Research (IOR) Bellinzona, Switzerland
ior.usi.ch Universities & institutes Cancer research institute affiliated with Università della Svizzera italiana, with programmes including lymphoma and prostate cancer.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Screening High-throughput synergy screening of blood-brain-barrier penetrant compounds identifies druggable targets that potentiate BTK inhibition in CNS lymphomas Preclinical models Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Transcriptional and epigenetic inducers of proximity as antitumor agents in marginal zone lymphomas Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents First characterization of the synthetic peptide CIGB-552 in B-cell lymphomas demonstrates antitumor activity in drug-resistant models and enhancement of BTK-targeted therapies Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents The CBP/EP300 inhibitor TT125-802 shows antitumor activity in marginal zone lymphoma models and can improve the effects of BTK inhibitors Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology FF01, a novel heavy chain antibody targeting the human endogenous retrovirus envelope, displays anti-lymphoma activity Immuno-oncology Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs BTK and BCL2 targeting with orelabrutinib (ICP-022) and mesutoclax (ICP-248): single-agent and combination activity in marginal zone lymphoma, including drug-resistant derivatives Drug design Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Natural extracts show anti-proliferative activity in lymphoma cells with resistance to targeted agents Drug design
START Center for Cancer Research San Antonio, TX
startresearch.com Cancer centres & hospitals Network of early-phase oncology clinical trial sites in the United States and Europe, including units in Madrid.	Talk Wed Nov 18 3–3:20pm Part of Plenary Session 1: The next wave of immune engagers in cancer therapy: beyond CD3 and beyond T cells Next generation multispecific immune engagers Immuno-oncology Session Wed Nov 18 4:15–5:45pm Workshop 2: Radiopharmaceuticals ADCs & radioligands Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Safety and Preliminary Activity of MTA-Cooperative PRMT5 Inhibitors (MTA-iPRMT5) in Patients with Advanced Solid Tumors Treated in a Phase I Clinical Trials Unit Drug design
BioNTech Mainz, Germany
biontech.com Biotech Immunotherapy company developing mRNA vaccines, cell therapies, bispecific antibodies and antibody-drug conjugates for cancer.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Preclinical evaluation of BNT329, a novel antibody-drug-conjugate targeting the sialyl Lewis A antigen CA19-9 ADCs & radioligands Plenary Fri Nov 20 11:15am–12pm Keynote lecture: Immunotherapy innovations Immuno-oncology
Centre de Recherche des Cordeliers Paris, France
crcordeliers.fr Universities & institutes Paris biomedical research centre run with Sorbonne Université, Université Paris Cité and Inserm.	Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Tumour immunology and inflammation Plasma complement activation is associated with favourable prognosis in luminal metastatic breast cancer Immuno-oncology Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Tumour immunology and inflammation Complement activation is associated with distinct functional states of membrane attack complex deposition in HER2-positive breast cancer Immuno-oncology